ES2227684T3 - Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco. - Google Patents

Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco.

Info

Publication number
ES2227684T3
ES2227684T3 ES97917418T ES97917418T ES2227684T3 ES 2227684 T3 ES2227684 T3 ES 2227684T3 ES 97917418 T ES97917418 T ES 97917418T ES 97917418 T ES97917418 T ES 97917418T ES 2227684 T3 ES2227684 T3 ES 2227684T3
Authority
ES
Spain
Prior art keywords
treatment
dry eye
active ingredient
albumina
conjunctive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97917418T
Other languages
English (en)
Inventor
Kazuo Tsubota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Application granted granted Critical
Publication of ES2227684T3 publication Critical patent/ES2227684T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION PRESENTA UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA LESION CORNEAL Y CONJUNTIVAL Y DEL OJO SECO QUE CONTIENE ALBUMINA COMO PRINCIPIO ACTIVO. LA COMPOSICION FARMACEUTICA TAMBIEN ES UTIL PARA AUMENTAR LA SECRECION DE MUCINA POR EL EPITELIO DE LA SUPERFICIE OCULAR. LA PRESENTE INVENCION PRESENTA TAMBIEN UN METODO PARA EL TRATAMIENTO DE LA LESION CORNEAL Y CONJUNTIVAL Y DEL OJO SECO QUE CONSISTE EN LA ADMINISTRACION, A SUJETO QUE REQUIERE DICHO TRATAMIENTO, DE ALBUMINA EN CANTIDAD SUFICIENTE. ADEMAS, LA PRESENTE INVENCION PRESENTA EL USO DE LA ALBUMINA PARA LA FABRICACION DE LA COMPOSICION FARMACEUTICA DE LA PRESENTE INVENCION.
ES97917418T 1996-04-19 1997-04-17 Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco. Expired - Lifetime ES2227684T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP9809096 1996-04-19
JP10686696 1996-04-26
US75294196A 1996-11-21 1996-11-21
US75292896A 1996-11-21 1996-11-21

Publications (1)

Publication Number Publication Date
ES2227684T3 true ES2227684T3 (es) 2005-04-01

Family

ID=27468604

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97917418T Expired - Lifetime ES2227684T3 (es) 1996-04-19 1997-04-17 Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco.

Country Status (11)

Country Link
US (2) US6043213A (es)
EP (1) EP0834320B1 (es)
JP (1) JP3058920B2 (es)
KR (1) KR100455475B1 (es)
CN (1) CN1124158C (es)
AT (1) ATE274918T1 (es)
CA (1) CA2225398C (es)
DE (1) DE69730476T2 (es)
ES (1) ES2227684T3 (es)
NO (1) NO320601B1 (es)
WO (1) WO1997039769A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1210949B1 (en) * 1999-07-28 2008-11-19 Morinaga Milk Industry Co., Ltd. Lactalbumin for the curative treatment of peptic ulcers
GB0019378D0 (en) 2000-08-07 2000-09-27 Saugstad Ola D Method
ES2300398T3 (es) * 2001-04-26 2008-06-16 R-Tech Ueno, Ltd. Uso de albumina en combinacion con factores de crecimiento para inhibir la apoptosis.
US20030211043A1 (en) * 2001-09-28 2003-11-13 Korb Donald R. Eye treatment
US20060234907A1 (en) * 2004-02-13 2006-10-19 Werner Gehringer Albumin solution and process for the production thereof
US8455016B2 (en) 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US7189697B2 (en) * 2004-04-13 2007-03-13 Trustees Of Tufts College Compositions and uses of a galectin for treatment of dry eye syndrome
US20060232060A1 (en) * 2005-04-13 2006-10-19 Assignee1 Pressure sensitive packing laminate overlay form combination and method of using same
WO2007033020A2 (en) * 2005-09-13 2007-03-22 Bausch & Lomb Incorporated Ophthalmic formulation for treatment of dry eye
US20080286211A1 (en) * 2007-04-27 2008-11-20 Barker Nicholas P Using mucin glycoproteins in combination with therapeutic agents to treat epithelial lesions and disorders of impaired mucin function
TW201000135A (en) * 2008-05-15 2010-01-01 R Tech Ueno Ltd Pharmaceutical composition for treating xerophthalmia and/or disorder of cornea/conjunctiva
KR101422571B1 (ko) 2009-10-13 2014-07-24 삼성전자 주식회사 받침대 및 이를 구비한 세탁기
NZ622403A (en) * 2009-11-27 2015-09-25 R Tech Ueno Ltd Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method
AU2013203609B2 (en) * 2009-11-27 2014-08-21 R-Tech Ueno, Ltd. Method for screening drug efficacious in treating dry eye and/or keratoconjunctival disorders and pharmaceutical composition obtained thereby
AU2011347237A1 (en) * 2010-12-21 2013-07-11 Recopharma Ab Tear substitutes
DE102015205293A1 (de) 2015-03-24 2016-09-29 Marc Schrott Verfahren zur Herstellung von Augentropfen
CN115350115B (zh) * 2016-04-01 2024-03-22 佰可姿国际私人有限公司 包含在细胞培养基中的白蛋白、透明质酸或胶原蛋白作为活性成分的化妆品组合物
MX2020009235A (es) * 2018-03-09 2023-01-16 Kiora Pharmaceuticals Gmbh Formulacion oftalmica.
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
WO2020021477A2 (en) 2018-07-27 2020-01-30 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating the eye
US11969454B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2024018452A1 (en) 2022-07-18 2024-01-25 Yeda Research And Development Co. Ltd. Albumin protein variants, production thereof and uses of same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57126422A (en) * 1981-01-29 1982-08-06 Green Cross Corp:The Stabilizing method of lysozyme pharmaceutical
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
CA1263606A (en) * 1985-05-29 1989-12-05 Jeffrey P. Gilbard Non-toxic opthalmic preparations
JPS6391331A (ja) * 1986-10-03 1988-04-22 Senjiyu Seiyaku Kk 眼科用水性組成物
JPH04505319A (ja) * 1989-04-04 1992-09-17 アルコン　ラボラトリーズ　インコーポレイテッド 創傷、切傷および擦傷に対する治療剤のデリバリーとしてのリポソームの使用
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
JPH05310592A (ja) * 1992-05-11 1993-11-22 Nichirei Corp 創傷治療剤及び医薬製剤
JPH06271478A (ja) * 1993-03-23 1994-09-27 Otsuka Pharmaceut Co Ltd ドライアイ治療剤
EP0637450A3 (en) * 1993-08-04 1995-04-05 Collagen Corp Method and composition for resuscitation of hereditary tissue.
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides

Also Published As

Publication number Publication date
CA2225398A1 (en) 1997-10-30
US6043213A (en) 2000-03-28
US6159930A (en) 2000-12-12
DE69730476D1 (de) 2004-10-07
CN1195296A (zh) 1998-10-07
DE69730476T2 (de) 2005-11-17
WO1997039769A1 (fr) 1997-10-30
EP0834320A4 (en) 2000-11-22
NO975962D0 (no) 1997-12-18
NO320601B1 (no) 2005-12-27
KR100455475B1 (ko) 2004-12-17
KR19990028235A (ko) 1999-04-15
JP3058920B2 (ja) 2000-07-04
CA2225398C (en) 2008-07-15
CN1124158C (zh) 2003-10-15
EP0834320A1 (en) 1998-04-08
NO975962L (no) 1998-02-18
ATE274918T1 (de) 2004-09-15
EP0834320B1 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
ES2227684T3 (es) Albumina como ingrediente activo para el tratamiento de lesiones conjuntivas y de la cornea y del ojo seco.
BR0012387A (pt) Composição para tratamento de distúrbios de secreção externa
IL153665A0 (en) Topical pharmaceutical formulations and methods of treatment
ES2458493T8 (es) Composición oftálmica tópica de fluprostenol para el tratamiento del glaucoma y de la hipertensión ocular
MX9405006A (es) Solucion oftalmica para lagrimas artificiales.
ES2708451T3 (es) Soluciones de bimatoprost y timolol sin conservantes
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
CA2436269A1 (en) Artificial tear composition containing a combination of three demulcents
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
KR890003387A (ko) 국소활성을 갖는 이중-가닥 RMAs조성물
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
EP2316420A1 (en) Method to reduce pain
US20030028163A1 (en) Additive for a sanitary napkin and a method of adding the same
TW202014194A (zh) 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
ES2208434T3 (es) Uso de la ubiquinona q10 para un tratamiento local y para la prevencion de las patologias oftamologicas posquirurgicas.
JP2002524418A (ja) 眼用組成物および使用法
US6103771A (en) Method of treating neuroma pain
ES2073245T3 (es) Agentes para el tratamiento de la cornea.
ES2579838T3 (es) Soluciones únicas para el cuidado de lentes de contacto que comprenden camomila
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
AU643772B2 (en) Use of hexetidine or its derivatives or salts for the preparation of a pharmaceutical composition for ophthalmological use
JP2017007995A (ja) 洗眼剤組成物及び洗眼方法
KR970704439A (ko) 눈의 염증 및/또는 상처의 예방 및 치료 방법(Method of preventing and treating ophthalmic inflammation and/or wound)
GR3018349T3 (en) Use of naproxen as mydriatic agent.
JP2005200411A (ja) 涙液層安定化剤